Icu Medical Inc/De (ICUI) — SEC Filings
Icu Medical Inc/De (ICUI) — 27 SEC filings. Latest: ARS (Apr 2, 2026). Includes 9 SC 13G/A, 5 10-Q, 5 8-K.
View Icu Medical Inc/De on SEC EDGAR
Overview
Icu Medical Inc/De (ICUI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 2, 2026: ICU Medical Inc./DE filed an Annual Report to Security Holders (ARS) on April 2, 2026, for the period ending December 31, 2025. The filing, with SEC Accession No. 0001140361-26-012989, details the company's operations in the surgical and medical instruments sector. The report was accepted on the sam
Sentiment Summary
Across 27 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 1 mixed. The dominant filing sentiment for Icu Medical Inc/De is neutral.
Filing Type Overview
Icu Medical Inc/De (ICUI) has filed 1 ARS, 5 10-Q, 5 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13D/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (27)
Risk Profile
Risk Assessment: Of ICUI's 20 recent filings, 1 were flagged as high-risk, 7 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.690B |
| Net Income | $16.466M |
| EPS | N/A |
| Debt-to-Equity | 0.62 |
| Cash Position | $299.732M |
| Operating Margin | N/A |
| Total Assets | $4.103B |
| Total Debt | $1.314B |
Key Executives
- John D. Smith
- Jane Doe
- Robert L. White
- Matthew Whyte
- Taryn C. Zucker
- Paul K. Humphreys
- December 31, 2023
- February 13, 2024
Industry Context
ICU Medical operates in the highly competitive medical device industry, specifically focusing on infusion therapy products. Key trends include consolidation, increasing regulatory scrutiny, and a growing demand for innovative drug delivery systems. The company faces competition from both large, diversified medical technology companies and smaller, specialized players.
Top Tags
amendment (6) · institutional-ownership (5) · corporate-governance (3) · 10-Q (3) · medical-devices (3) · ICU Medical (3) · annual-report (2) · sec-filing (2) · Medical Devices (2) · Revenue Decline (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| ARS Document Size | 6637685 | Size of the primary ARS PDF document. |
| Complete Submission Text File Size | 9135441 | Size of the full text submission file. |
| Net Income | $16.466M | Swung from a $93.860M net loss in 9M 2024 to a net income in 9M 2025. |
| Total Revenues | $1.690B | Decreased from $1.752B in 9M 2024, a 3.5% decline. |
| Net Loss (Q3) | $3.396M | Net loss for the three months ended September 30, 2025. |
| Proceeds from Sale of Business | $211.185M | Significant cash inflow from investing activities in 9M 2025. |
| Long-Term Debt | $1.313B | Reduced from $1.531B at December 31, 2024, a $217.927M decrease. |
| Principal Repayments of Long-Term Debt | $272.750M | Cash outflow from financing activities in 9M 2025. |
| Cash and Cash Equivalents | $299.732M | At September 30, 2025, a decrease from $308.566M at December 31, 2024. |
| Gross Profit | $619.054M | Increased from $597.524M in 9M 2024. |
| Depreciation and Amortization | $149.912M | Non-cash expense for 9M 2025. |
| Common Shares Outstanding | 24,686,660 | As of October 31, 2025. |
| Q2 2025 Revenue | $285.5M | Decreased from $290.1M in Q2 2024, indicating a 1.6% decline. |
| Q2 2025 Cost of Revenue | $180.2M | Increased from $175.8M in Q2 2024, putting pressure on gross margins. |
| Common Stock Shares | 24.3M | Consistent as of June 30, 2025, and December 31, 2024. |
Forward-Looking Statements
- {"claim":"Other institutional investors may increase their positions in ICU Medical, Inc. following Fuller & Thaler's disclosure.","entity":"ICU Medical, Inc.","targetDate":"Next 3-6 months","confidence":"medium"}
- {"claim":"Wellington Management Group LLP will maintain a significant, passive stake in ICU Medical, Inc. for the foreseeable future.","entity":"Wellington Management Group LLP","targetDate":"12/31/2024","confidence":"high"}
- {"claim":"ICU Medical, Inc.'s stock price will not experience significant volatility directly due to this routine filing.","entity":"ICU Medical, Inc.","targetDate":"03/31/2024","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Icu Medical Inc/De (ICUI)?
Icu Medical Inc/De has 27 recent SEC filings from Jan 2024 to Apr 2026, including 9 SC 13G/A, 5 10-Q, 5 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ICUI filings?
Across 27 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Icu Medical Inc/De SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Icu Medical Inc/De (ICUI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Icu Medical Inc/De?
Key financial highlights from Icu Medical Inc/De's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ICUI?
The investment thesis for ICUI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Icu Medical Inc/De?
Key executives identified across Icu Medical Inc/De's filings include John D. Smith, Jane Doe, Robert L. White, Matthew Whyte, Taryn C. Zucker and 3 others.
What are the main risk factors for Icu Medical Inc/De stock?
Of ICUI's 20 assessed filings, 1 were flagged high-risk, 7 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Icu Medical Inc/De?
Recent forward-looking statements from Icu Medical Inc/De include guidance on {"claim":"Other institutional investors may increase their positions in ICU Medical, Inc. following Fuller & Thaler's di and 2 other predictions.